A Phase 2b, Multicenter, Treatment-Arm Blind, Safety And Efficacy 32-Week Extension Study Of Apremilast (CC-10004) In Subjects Who Completed The Treatment Phase Of The Core Study CC-10004-PSOR-005 [EXTENSION OF 700042305]

Trial Profile

A Phase 2b, Multicenter, Treatment-Arm Blind, Safety And Efficacy 32-Week Extension Study Of Apremilast (CC-10004) In Subjects Who Completed The Treatment Phase Of The Core Study CC-10004-PSOR-005 [EXTENSION OF 700042305]

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2014

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 12 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top